CNS Pharmaceuticals announces 1-for-50 reverse stock split

CNS Pharmaceuticals announced a 1-for-50 reverse split of its common stock, effective at 4:01 PM ET on June 4, 2024. Beginning on June 5, 2024, the Company’s common stock will continue to trade on The Nasdaq Capital Market on a split adjusted basis under the trading symbol “CNSP“, but will trade under the following new CUSIP number: 18978H300. The reverse stock split is primarily intended to increase the Company’s per share trading price and bring the Company into compliance with the Nasdaq’s listing requirement regarding minimum share price.